CY1108363T1 - Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια του μη-hodgkin λεμφωματος - Google Patents
Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια του μη-hodgkin λεμφωματοςInfo
- Publication number
- CY1108363T1 CY1108363T1 CY20081101031T CY081101031T CY1108363T1 CY 1108363 T1 CY1108363 T1 CY 1108363T1 CY 20081101031 T CY20081101031 T CY 20081101031T CY 081101031 T CY081101031 T CY 081101031T CY 1108363 T1 CY1108363 T1 CY 1108363T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hodgkin
- treatment
- arsenic trioxide
- length
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Epoxy Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Η εφεύρεση αναφέρεται στη χρήση των ενώσεων αρσενικού για την θεραπεία μια ποικιλίας νεοπλαστικών ασθενειών συγκεκριμένα του λεμφώματος. Περαιτέρω, οι ενώσεις αρσενικού μπορούν να χρησιμοποιηθούν για να θεραπεύσουν τις μεταστατιτικές νεοπλαστικές ασθένειες.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6237597P | 1997-10-15 | 1997-10-15 | |
EP03019628A EP1391206B1 (en) | 1997-10-15 | 1998-10-15 | Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108363T1 true CY1108363T1 (el) | 2014-02-12 |
Family
ID=22042073
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081101031T CY1108363T1 (el) | 1997-10-15 | 2008-09-24 | Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια του μη-hodgkin λεμφωματος |
CY20081101395T CY1110055T1 (el) | 1997-10-15 | 2008-12-02 | Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια του πολλαπλου μυελωματος |
CY20081101430T CY1110057T1 (el) | 1997-10-15 | 2008-12-10 | Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια ενος ογκου του κεντρικου νευρικου συστηματος |
CY20111100361T CY1111379T1 (el) | 1997-10-15 | 2011-04-05 | Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση πρωτογενων και μεταστατικων-νεοπλασματικων ασθενειων με τη χρηση τριοξειδιου του αρσενικου |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081101395T CY1110055T1 (el) | 1997-10-15 | 2008-12-02 | Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια του πολλαπλου μυελωματος |
CY20081101430T CY1110057T1 (el) | 1997-10-15 | 2008-12-10 | Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια ενος ογκου του κεντρικου νευρικου συστηματος |
CY20111100361T CY1111379T1 (el) | 1997-10-15 | 2011-04-05 | Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση πρωτογενων και μεταστατικων-νεοπλασματικων ασθενειων με τη χρηση τριοξειδιου του αρσενικου |
Country Status (21)
Country | Link |
---|---|
US (9) | US6875451B2 (el) |
EP (9) | EP1466607A1 (el) |
JP (1) | JP2001519366A (el) |
KR (1) | KR20010015755A (el) |
CN (1) | CN1282218A (el) |
AT (4) | ATE399560T1 (el) |
AU (1) | AU751932B2 (el) |
BR (1) | BR9813085A (el) |
CA (1) | CA2307208A1 (el) |
CY (4) | CY1108363T1 (el) |
DE (4) | DE69842094D1 (el) |
DK (4) | DK1378240T3 (el) |
ES (4) | ES2358624T3 (el) |
HK (3) | HK1061198A1 (el) |
IL (1) | IL135620A0 (el) |
NO (1) | NO20001977L (el) |
NZ (1) | NZ503973A (el) |
PL (1) | PL339909A1 (el) |
PT (4) | PT2018858E (el) |
TR (1) | TR200001959T2 (el) |
WO (1) | WO1999018798A1 (el) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID25622A (id) * | 1997-11-10 | 2000-10-19 | Sloan Kettering Inst Cancer | Proses untuk memproduksi formulasi arsenat trioksida dan metoda untuk mengobati kanker dengan menggunakan arsenat trioksida atau melarsoprol |
CN1233476A (zh) * | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
AUPQ296799A0 (en) | 1999-09-20 | 1999-10-14 | Unisearch Limited | A cell-membrane impermeable trivalent organoarsenical derivative and use thereof |
AUPR379801A0 (en) | 2001-03-19 | 2001-04-12 | Unisearch Limited | Use of a substantially cell membrane impermeable compound for treating arthritis |
US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
WO2003003855A1 (de) * | 2001-07-05 | 2003-01-16 | Luedke Hans-Werner | Nahrungsergänzungsprodukt oder arzneimittel gegen bestimmte mangelzustände und hirnfunktionsstörungen |
AUPR874601A0 (en) * | 2001-11-08 | 2001-11-29 | Unisearch Limited | Selective targeting of apoptotic cells |
KR20030058019A (ko) * | 2001-12-29 | 2003-07-07 | 한국원자력연구소 | 삼산화비소(As₂O₃)를 유효 성분으로 포함하는 방사선치료증진제 |
US6911471B2 (en) * | 2002-01-07 | 2005-06-28 | The Texas A&M University System | S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
MXPA04009898A (es) * | 2002-04-10 | 2005-06-20 | Korea Microbiological Lab Ltd | Composicion farmaceutica que comprende arsenita para el tratamiento de tumores malignos. |
FR2838965B1 (fr) | 2002-04-26 | 2004-06-25 | Centre Nat Rech Scient | Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme |
US8394422B2 (en) * | 2002-04-26 | 2013-03-12 | Centre National De La Recherche Scientifique (Cnrs) | Arsenic therapy for autoimmune and/or inflammatory diseases in mice and humans |
KR100492940B1 (ko) * | 2002-05-27 | 2005-06-02 | 김종배 | 항종양활성 증진용 조성물 |
US20080089949A1 (en) * | 2006-10-13 | 2008-04-17 | Yok-Lam Kwong | Method for treating cancer using oral arsenic trioxide |
US20080166425A1 (en) * | 2002-10-09 | 2008-07-10 | The University Of Hong Kong | Method for inhibiting cancer using arsenic trioxide |
US8906422B2 (en) * | 2002-10-09 | 2014-12-09 | The University Of Hong Kong | Method for inhibiting cancer using arsenic trioxide |
US7521071B2 (en) * | 2002-10-09 | 2009-04-21 | Versitech Limited | Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
CA2504935C (en) | 2002-11-07 | 2012-04-10 | Unisearch Limited | Induction of the mitochondrial permeability transition |
US20050053664A1 (en) | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
WO2005062810A2 (en) * | 2003-12-18 | 2005-07-14 | Mediscovery, Llc | Treatment of primary and metastatic neoplastic diseases with tetraarsenic decaoxide |
AU2005219876A1 (en) * | 2004-03-01 | 2005-09-15 | Peptimmune, Inc. | Methods and compositions for treatment of autoimmune diseases |
US20050196464A1 (en) * | 2004-03-03 | 2005-09-08 | Tty Biopharm Company Limited | Method and pharmaceutical composition for treatment of skin neoplasm |
US20050208149A1 (en) * | 2004-03-18 | 2005-09-22 | Tty Biopharm Limited Company | Use of arsenic-containing pharmaceutical composition in combination with radiation therapy for cancer treatment |
US20060194725A1 (en) * | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
US7655221B2 (en) * | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
US20060003966A1 (en) | 2004-06-16 | 2006-01-05 | Jack Arbiser | Carbazole formulations for the treatment of psoriasis and angiogenesis |
TW201440760A (zh) * | 2004-07-16 | 2014-11-01 | Texas A & M Univ Sys | 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物 |
EP1789107B1 (en) * | 2004-08-30 | 2009-05-27 | Interstitial Therapeutics | Medical stent provided with inhibitors of atp synthesis |
US8258181B2 (en) | 2005-03-23 | 2012-09-04 | Florida Atlantic University | Treatment or prevention of cancer and precancerous disorders |
EP1721615A1 (en) * | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
AU2006285329B2 (en) * | 2005-07-29 | 2012-10-04 | Solasia Pharma K.K. | Compounds and methods for the treatment of cancer |
US20110020434A1 (en) * | 2005-09-02 | 2011-01-27 | O'halloran Thomas V | Nanoparticle arsenic-platinum compositions |
WO2007028154A2 (en) * | 2005-09-02 | 2007-03-08 | Northwestern University | Encapsulated arsenic drugs |
US8784899B2 (en) * | 2005-10-04 | 2014-07-22 | Samuel Waxman Cancer Research Foundation | Compositions and methods for cancer treatment |
US20080233207A1 (en) * | 2006-01-04 | 2008-09-25 | Sheptovitsky Yelena G | Injectable and Infusable Mercury Compositions and Methods for Treating Cancer |
ITMI20060480A1 (it) * | 2006-03-16 | 2007-09-17 | Solvay Solexis Spa | Usom di perfluoropolimeri nella dtermibnazione della costante di legame recettore-ligando |
US20090018142A9 (en) * | 2006-05-02 | 2009-01-15 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
TW200829261A (en) * | 2006-09-29 | 2008-07-16 | Ziopharm Oncology Inc | Method for controlling angiogenesis in animals |
US20080089951A1 (en) * | 2006-10-11 | 2008-04-17 | The University Of Hong Kong | Method for Inhibiting Cancer Using Arsenic Trioxide |
CN101595115B (zh) | 2006-11-01 | 2012-07-18 | 新南部创新有限公司 | 有机-氧化砷化合物及其用途 |
US8945505B2 (en) | 2007-02-02 | 2015-02-03 | Panaphix, Inc. | Use of arsenic compounds for treatment of pain and inflammation |
BRPI0806365B8 (pt) * | 2007-02-06 | 2021-05-25 | Lixte Biotechnology Holdings Inc | composto, uso do composto, composição farmacêutica e uso da composição farmacêutica |
US20090035292A1 (en) * | 2007-08-03 | 2009-02-05 | Kovach John S | Use of phosphatases to treat neuroblastomas and medulloblastomas |
JP5730575B2 (ja) | 2007-10-01 | 2015-06-10 | リクスト・バイオテクノロジー,インコーポレイテッド | Hdac阻害剤 |
WO2009061373A1 (en) * | 2007-11-02 | 2009-05-14 | Ziopharm Oncology, Inc. | Combination therapy with organic arsenicals |
CN101874034A (zh) * | 2007-12-12 | 2010-10-27 | Zio医药肿瘤学公司 | 用于治疗癌症的化合物和方法 |
US20090246291A1 (en) * | 2008-03-27 | 2009-10-01 | Angelika Burger | Method and compositions for treatment of cancer |
US8227473B2 (en) | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
WO2010014220A1 (en) * | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
WO2010014141A1 (en) * | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
CN104800828A (zh) | 2008-08-20 | 2015-07-29 | 日本苏爱康制药有限公司 | 用于治疗癌症的有机砷化合物和方法 |
KR101100786B1 (ko) * | 2008-12-16 | 2011-12-29 | (주)천지산 | 암에 대한 방사선 치료 증진용 조성물 |
JP5710619B2 (ja) * | 2009-09-10 | 2015-04-30 | コミノックス・インコーポレイテッド | 癌幹細胞を標的とした薬剤耐性癌治療法 |
MX2012002922A (es) * | 2009-09-18 | 2012-09-07 | Kominox Inc | Metodos para tratar tumores del cerebro. |
US20120015023A1 (en) * | 2010-04-15 | 2012-01-19 | Antimisiaris Sophia G | Treatment of tumors prostate with arsonoliposomes |
WO2014152330A1 (en) * | 2013-03-15 | 2014-09-25 | Stc.Unm | Arsenic-based treatment of cancers and inflammatory disorders |
WO2014151317A1 (en) * | 2013-03-15 | 2014-09-25 | Rush University Medical Center | Methods for treating cancer |
MX2015014249A (es) | 2013-04-09 | 2016-06-02 | Lixte Biotechnology Inc | Formulaciones de oxabicicloheptanos y oxabicicloheptenos. |
FR3004949B1 (fr) * | 2013-04-26 | 2016-02-05 | Centre Nat Rech Scient | Traitement de maladies autoimmunes et inflammatoires par les composes de l'arsenic as203 et/ou as205 administres par voie locale |
US9700580B1 (en) | 2016-06-14 | 2017-07-11 | Marguerite Harning | Method for cancer treatment |
PE20191544A1 (es) | 2016-12-01 | 2019-10-24 | Eupharma Pty Ltd | Composiciones de arsenico |
KR101844050B1 (ko) * | 2016-12-09 | 2018-05-14 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물 |
WO2018209343A1 (en) * | 2017-05-12 | 2018-11-15 | Rajur Sharanappa Basappa | Novel methods, compounds, and compositions: small molecule anticancer agents |
WO2019234112A1 (en) | 2018-06-05 | 2019-12-12 | Katholieke Universiteit Leuven | Combination treatment of arsenic oxide and antiandrogens |
CN112675197A (zh) * | 2021-01-22 | 2021-04-20 | 中山大学孙逸仙纪念医院 | 一种用于儿童Hedgehog信号通路驱动肿瘤的药物组合物 |
CN114028425A (zh) * | 2021-09-24 | 2022-02-11 | 上海交通大学医学院附属新华医院 | 硫化砷及其与放疗联合在治疗横纹肌肉瘤上的应用 |
CN115634287A (zh) * | 2022-09-30 | 2023-01-24 | 苏州系统医学研究所 | 一种基于砷化合物的肿瘤疫苗及其制备方法和应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US132275A (en) | 1872-10-15 | Improvement in medical compounds | ||
US232807A (en) | 1880-10-05 | Herbert e | ||
US3700498A (en) | 1970-12-10 | 1972-10-24 | Ibm | Process for making electrophotographic plates |
JPS5188620A (en) | 1975-01-31 | 1976-08-03 | Jintainokenkonoiji kotonigannitaishitekonoojusuru noshukuionekinoseizoho | |
DE3003635C2 (de) | 1980-02-01 | 1985-07-11 | Klöckner-Humboldt-Deutz AG, 5000 Köln | Verfahren und Vorrichtung zur Entarsenierung arsenhaltiger Materialien |
US4599305A (en) * | 1984-07-16 | 1986-07-08 | The Regents Of The University Of California | Method and composition for detection of human chronic myelogenous leukemia |
NL8502929A (nl) * | 1985-10-25 | 1987-05-18 | Tno | Groep viii-overgangsmetaal-complexen, werkwijze voor het bereiden daarvan, werkwijze voor het bereiden van een geneesmiddel met toepassing van een dergelijke groep viii-overgangsmetaal-complex voor de behandeling van kanker, alsmede aldus verkregen gevormd geneesmiddel. |
US5759837A (en) | 1989-01-17 | 1998-06-02 | John Hopkins University | Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway |
CN1061908A (zh) | 1991-12-21 | 1992-06-17 | 江西省妇产医院 | 一种治癌药物的制造方法 |
CN1060935C (zh) | 1992-05-31 | 2001-01-24 | 丛繁滋 | 用于癌病灶直接给药的砷制剂的制备方法 |
CN1044777C (zh) | 1992-07-06 | 1999-08-25 | 杨世泽 | 癌痛止痛膏的配制方法 |
AU682007B2 (en) | 1992-07-24 | 1997-09-18 | Johns Hopkins University, The | Use of inhibitors of fatty acid synthesis for treating cancer |
FR2699820B3 (fr) * | 1992-12-24 | 1995-03-10 | Eric Pichot | Traitement homéopathique préventif des dysmytoses (cancer, leucémie) et malformations ou mutations génétiques. |
DE4317331A1 (de) * | 1993-05-25 | 1994-12-01 | Reischle Karl Georg | Behandlung von Schädigungen des Immunsystems |
ITTO930510A1 (it) | 1993-07-09 | 1993-10-07 | Walter Tarello | Farmaci attivi contro la chronic fatigue syndrome (c.f.s.) |
DE69434093T2 (de) | 1994-02-18 | 2006-03-09 | Tamara Vasilievna Vorobieva | Substanz mit immunonodulierender wirkung und zur verringerung der disfunktion des gewebezellenregelungssystems |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
CN1119113A (zh) | 1994-09-22 | 1996-03-27 | 衣永德 | 复方癌复康胶囊及制备方法 |
CN1122700A (zh) | 1994-11-08 | 1996-05-22 | 付知中 | 一种治疗乳腺疾病、肿瘤疮毒的散剂及其制备方法 |
LV11667B (en) * | 1995-08-14 | 1997-06-20 | Tamara Vorobieva | Remedy for renewal of disordered function of immunomodulation and cell tissue reproduction adjustors |
CN1044559C (zh) | 1995-08-23 | 1999-08-11 | 哈尔滨医科大学附属第一医院 | 抗白血病、肝癌、淋巴瘤注射液 |
US5748699A (en) * | 1995-10-06 | 1998-05-05 | Smith; Donald O. | Apparatus for applying X-rays to an interior surface of a body cavity |
CN1058620C (zh) | 1995-11-12 | 2000-11-22 | 卢颖 | 一种治疗癌症的外用中成药及配备生产工艺 |
CN1052648C (zh) | 1995-12-03 | 2000-05-24 | 唐书生 | 癌瘤消肿止痛膏 |
ID25622A (id) | 1997-11-10 | 2000-10-19 | Sloan Kettering Inst Cancer | Proses untuk memproduksi formulasi arsenat trioksida dan metoda untuk mengobati kanker dengan menggunakan arsenat trioksida atau melarsoprol |
CN1233476A (zh) | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
ES2285251T3 (es) * | 2002-09-24 | 2007-11-16 | Novartis Ag | Uso de derivados 4-piridilmetilftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos. |
US20050196464A1 (en) * | 2004-03-03 | 2005-09-08 | Tty Biopharm Company Limited | Method and pharmaceutical composition for treatment of skin neoplasm |
-
1998
- 1998-10-15 DE DE69842094T patent/DE69842094D1/de not_active Expired - Lifetime
- 1998-10-15 EP EP04007847A patent/EP1466607A1/en not_active Ceased
- 1998-10-15 EP EP98953552A patent/EP1022951A4/en not_active Withdrawn
- 1998-10-15 AT AT03019628T patent/ATE399560T1/de active
- 1998-10-15 EP EP03019595A patent/EP1374875A3/en not_active Withdrawn
- 1998-10-15 PT PT08016665T patent/PT2018858E/pt unknown
- 1998-10-15 AU AU10893/99A patent/AU751932B2/en not_active Expired
- 1998-10-15 AT AT05077338T patent/ATE409043T1/de active
- 1998-10-15 PT PT05077338T patent/PT1621077E/pt unknown
- 1998-10-15 DK DK03019594T patent/DK1378240T3/da active
- 1998-10-15 DE DE69840006T patent/DE69840006D1/de not_active Expired - Lifetime
- 1998-10-15 TR TR2000/01959T patent/TR200001959T2/xx unknown
- 1998-10-15 EP EP03029713A patent/EP1419778A1/en not_active Ceased
- 1998-10-15 DE DE69840057T patent/DE69840057D1/de not_active Expired - Lifetime
- 1998-10-15 DK DK03019628T patent/DK1391206T3/da active
- 1998-10-15 WO PCT/US1998/021782 patent/WO1999018798A1/en not_active Application Discontinuation
- 1998-10-15 PT PT03019594T patent/PT1378240E/pt unknown
- 1998-10-15 US US09/173,531 patent/US6875451B2/en not_active Expired - Lifetime
- 1998-10-15 PL PL98339909A patent/PL339909A1/xx unknown
- 1998-10-15 ES ES08016665T patent/ES2358624T3/es not_active Expired - Lifetime
- 1998-10-15 ES ES05077338T patent/ES2313201T3/es not_active Expired - Lifetime
- 1998-10-15 NZ NZ503973A patent/NZ503973A/en unknown
- 1998-10-15 IL IL13562098A patent/IL135620A0/xx unknown
- 1998-10-15 DK DK08016665.5T patent/DK2018858T3/da active
- 1998-10-15 EP EP08016665A patent/EP2018858B1/en not_active Expired - Lifetime
- 1998-10-15 ES ES03019594T patent/ES2312701T3/es not_active Expired - Lifetime
- 1998-10-15 EP EP03019628A patent/EP1391206B1/en not_active Expired - Lifetime
- 1998-10-15 ES ES03019628T patent/ES2309258T3/es not_active Expired - Lifetime
- 1998-10-15 CN CN98812218A patent/CN1282218A/zh active Pending
- 1998-10-15 BR BR9813085-4A patent/BR9813085A/pt not_active IP Right Cessation
- 1998-10-15 EP EP05077338A patent/EP1621077B1/en not_active Expired - Lifetime
- 1998-10-15 AT AT03019594T patent/ATE407683T1/de active
- 1998-10-15 PT PT03019628T patent/PT1391206E/pt unknown
- 1998-10-15 AT AT08016665T patent/ATE493979T1/de active
- 1998-10-15 DK DK05077338T patent/DK1621077T3/da active
- 1998-10-15 EP EP03019594A patent/EP1378240B1/en not_active Expired - Lifetime
- 1998-10-15 DE DE69839682T patent/DE69839682D1/de not_active Expired - Lifetime
- 1998-10-15 EP EP03019629A patent/EP1378241A1/en not_active Withdrawn
- 1998-10-15 CA CA002307208A patent/CA2307208A1/en not_active Abandoned
- 1998-10-15 JP JP2000515442A patent/JP2001519366A/ja active Pending
- 1998-10-15 KR KR1020007003973A patent/KR20010015755A/ko not_active Application Discontinuation
-
2000
- 2000-04-14 NO NO20001977A patent/NO20001977L/no not_active Application Discontinuation
-
2001
- 2001-01-29 HK HK04104292A patent/HK1061198A1/xx not_active IP Right Cessation
- 2001-01-29 HK HK04104293.2A patent/HK1061199A1/xx not_active IP Right Cessation
-
2003
- 2003-08-14 US US10/640,399 patent/US7163703B2/en not_active Expired - Lifetime
- 2003-08-14 US US10/640,403 patent/US7132116B2/en not_active Expired - Lifetime
- 2003-08-28 US US10/649,944 patent/US20040047916A1/en not_active Abandoned
- 2003-08-28 US US10/649,776 patent/US7179493B2/en not_active Expired - Lifetime
- 2003-11-03 US US10/698,625 patent/US7205001B2/en not_active Expired - Lifetime
-
2004
- 2004-02-12 US US10/776,504 patent/US20040161475A1/en not_active Abandoned
- 2004-02-27 US US10/789,628 patent/US20040197421A1/en not_active Abandoned
- 2004-02-27 US US10/789,604 patent/US20040197420A1/en not_active Abandoned
-
2006
- 2006-07-25 HK HK06108235.2A patent/HK1085886A1/xx not_active IP Right Cessation
-
2008
- 2008-09-24 CY CY20081101031T patent/CY1108363T1/el unknown
- 2008-12-02 CY CY20081101395T patent/CY1110055T1/el unknown
- 2008-12-10 CY CY20081101430T patent/CY1110057T1/el unknown
-
2011
- 2011-04-05 CY CY20111100361T patent/CY1111379T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108363T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια του μη-hodgkin λεμφωματος | |
ITMI990375A1 (it) | Trattamento del cancro co epotiloni | |
BR9707125A (pt) | Composições e processos para o tratamento e diagnóstico de câncer de mama | |
IL150767A (en) | Benzophyrene compounds and their use in the manufacture of drugs for the treatment of estrogen-sensitive diseases such as endometrial cancer | |
ATE415979T1 (de) | Behandlung mit anti-erbb2 antikörpern | |
ATE243692T1 (de) | Arylaminderivate und ihre verwendung als antitelomerasemittel | |
ATE239509T1 (de) | Konjugate zur behandlung von prostatakrebs | |
WO2000018439A3 (de) | Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren | |
TR199800443T1 (xx) | Hidroliz y�kseltici taksan hidrofobik t�revleri. | |
DE69927688D1 (de) | Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs | |
IL97055A0 (en) | Pharmaceutical compositions for sensitizing tumor cells comprising quinazolinedione derivatives | |
ID22718A (id) | Senyawa-senyawa tetrahidropirido | |
DZ2665A1 (fr) | Conjugués utiles pour le traitement du cancer de la prostate. | |
BR0215689A (pt) | Composição farmacêutica compreendendo arsênico para o tratamento de malignidade | |
AU5302599A (en) | Method for diagnosing bone metastasis of malignant tumor | |
ATE306255T1 (de) | 19-nor-vitamin d3 derivate mit calciumspiegel erhöhender wirkung | |
ATE329597T1 (de) | Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren | |
MX9701832A (es) | Nuevos profarmacos para la terapia de tumores y enfermedades inflamatorias. | |
DE60016194D1 (de) | Radioaktives cisplatin zur krebsbehandlung. |